Mankind Pharma Limited develops, manufactures, and markets pharmaceutical formulations and consumer healthcare products primarily in India and interna...
| Metric Name | Value | Trend | |
|---|---|---|---|
| Dividend Yield | 0.0% | ||
| P/E Ratio | 52.1x | ||
| Revenue | 116.4 B | ||
| Net Income to Company | 20.631 B |
| MANKIND | Peers | Sector | |
|---|---|---|---|
Market Cap | 1,064.2 B | 434.1 B | 5.469 B |
Price % of 52 Week High | 84.4% | 80.4% | 60.4% |
Dividend Yield | 0.0% | 0.8% | 0.0% |
Shareholder Yield | -0.3% | 1.1% | -0.7% |
1 Year Price Total Return | 10.2% | 9.6% | -12.0% |
Beta (5 Year) | - | 0.48 | 0.64 |
| (presentment in millions) | Trailing Twelve Months | Fiscal Quarters | |||
|---|---|---|---|---|---|
| Period Ending | Mar-23 | Mar-24 | Dec-24 | Dec-23 | Dec-24 |
| Income Statement | |||||
| Revenue | 87,494 | 103,348 | 116,410 | 26,070 | 32,300 |
| Operating Income | 15,883 | 21,518 | 24,573 | 4,968 | 6,375 |
| Net Profit | 12,819 | 19,129 | 20,414 | 4,538 | 3,802 |
| Diluted EPS | 32 | 47.68 | 50.81 | 11.31 | 9.44 |
| EBITDA | 19,051 | 25,366 | 28,931 | 5,760 | 7,337 |
| Balance Sheet | |||||
| Cash & ST Invest. | 15,216 | 33,865 | 47,267 | 23,259 | 47,267 |
| Current Assets | 43,279 | 65,682 | |||
| Total Assets | 97,154 | 119,633 | |||
| Current Liabilities | 18,631 | 21,197 | |||
| Total Liabilities | 20,922 | 23,875 | |||
| Total Equity | 76,233 | 95,758 | 107,893 | 86,336 | 107,893 |
| Total Debt | 1,704 | 2,072 | 4,821 | 1,794 | 4,821 |
| Cash Flow Statement | |||||
| Cash Flow Operations | 18,133 | 21,524 | |||
| Cash From Investing | (10,541) | (20,817) | |||
| Cash From Financing | (7,397) | 53 | |||
| Free Cash Flow | 10,243 | 18,371 | 19,993 | 0.00 | - |